Karin Walker

Direttore/Membro del Consiglio presso CYCLACEL PHARMACEUTICALS, INC.

Patrimonio netto: 6 696 $ in data 30/04/2024

60 anni

Health Technology

Process Industries

Finance

Posizioni attive di Karin Walker

Società	Posizione	Inizio	Fine
PROTHENA CORPORATION PLC	Comptroller/Controller/Auditor	20/05/2013	-
CYCLACEL PHARMACEUTICALS, INC.	Direttore/Membro del Consiglio	09/11/2020	-
CYCLACEL PHARMACEUTICALS, INC.	Independent Dir/Board Member	09/11/2020	-

Società	Posizione	Inizio	Fine
VINCERX PHARMA, INC.	Direttore/Membro del Consiglio	05/03/2020	23/12/2020
VINCERX PHARMA, INC.	Independent Dir/Board Member	05/03/2020	23/12/2020
AFFYMAX, INC.	Comptroller/Controller/Auditor	02/10/2012	01/05/2013
AMYRIS, INC.	Comptroller/Controller/Auditor	01/01/2009	01/01/2012
CV Therapeutics, Inc. CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases	Comptroller/Controller/Auditor	01/01/2006	01/01/2009
Ernst & Young US LLP Ernst & Young US LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young US LLP was engaged in providing accounting services. The company was headquartered in Pittsburgh, PA.	Corporate Officer/Principal	-	-

California Polytechnic State University (San Luis Obispo)

Undergraduate Degree

Distribuzione geografica

Stati Uniti	8
Irlanda	2

Posizioni

Comptroller/Controller/Auditor	4
Director/Board Member	2
Independent Dir/Board Member	2

Settori

Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Società quotate in Borsa	4
AFFYMAX, INC.	Health Technology
PROTHENA CORPORATION PLC	Health Technology
AMYRIS, INC.	Process Industries
CYCLACEL PHARMACEUTICALS, INC.	Health Technology

Aziende private	3
CV Therapeutics, Inc. CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases	Health Technology
LifeSci Acquisition Corp. LifeSci Acquisition Corp. Financial ConglomeratesFinance LifeSci Acquisition Corp. operates as a blank check company. It was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities. The company was founded on December 19, 2018 and is headquartered in New York, NY.	Finance
Ernst & Young US LLP Ernst & Young US LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young US LLP was engaged in providing accounting services. The company was headquartered in Pittsburgh, PA.	Commercial Services